$1.79
23.34% yesterday
Nasdaq, Apr 07, 10:19 pm CET
ISIN
US52886X1072
Symbol
LXEO
Sector
Industry

Lexeo Therapeutics Stock price

$1.79
-0.91 33.70% 1M
-6.73 78.99% 6M
-4.79 72.80% YTD
-11.37 86.40% 1Y
-9.21 83.73% 3Y
-9.21 83.73% 5Y
-9.21 83.73% 10Y
Nasdaq, Closing price Mon, Apr 07 2025
-0.55 23.34%
ISIN
US52886X1072
Symbol
LXEO
Sector
Industry

Key metrics

Market capitalization $59.42m
Enterprise Value $-52.18m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.64
P/B ratio (TTM) P/B ratio 0.51
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-105.77m
Free Cash Flow (TTM) Free Cash Flow $-81.63m
Cash position $121.52m
EPS (TTM) EPS $-3.09
P/E forward negative
Short interest 7.49%
Show more

Is Lexeo Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Lexeo Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Lexeo Therapeutics forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Lexeo Therapeutics forecast:

Buy
100%

Financial data from Lexeo Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 2 2
9% 9%
-
-2 -2
9% 9%
-
- Selling and Administrative Expenses 28 28
136% 136%
-
- Research and Development Expense 74 74
39% 39%
-
-104 -104
56% 56%
-
- Depreciation and Amortization 2 2
9% 9%
-
EBIT (Operating Income) EBIT -106 -106
54% 54%
-
Net Profit -98 -98
48% 48%
-

In millions USD.

Don't miss a Thing! We will send you all news about Lexeo Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexeo Therapeutics Stock News

Neutral
GlobeNewsWire
about 20 hours ago
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
Negative
MarketBeat
14 days ago
The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price surges in Tonix Pharmaceuticals NASDAQ: TNXP and Lexeo Therapeutics NASDAQ: LXEO. The biotech industry is known for its volatile price swings, often influenced by clinical trial results and regulatory decisions.
Neutral
GlobeNewsWire
15 days ago
Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from baseline rather than numerical threshold Interim update from cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial: observed 71% and 115% increases in P...
More Lexeo Therapeutics News

Company Profile

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Head office United States
CEO R. Townsend
Employees 72
Founded 2017
Website www.lexeotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today